Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs ISRG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ISRG Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

ISRG Overall Winner 6-Pillar Tally: SYK 2 – 4 ISRG Matrix Metrics: SYK 3 – 7 ISRG

As of Nov 16, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas ISRG carries 43.4/100 (HOLD) at $439.50 (35.6x Forward P/E, 31.7% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ISRG 43.4/100 HOLD), ISRG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.7% vs. 24.0% operating margin) and revenue trajectory (+21.7% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs ISRG
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
ISRG NASDAQ Head-to-Head Winner
Intuitive Surgical Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$439.50
-0.92% 1D
Market Cap $152.5B
TTM Revenue $11.6B
Forward P/E 35.6x
Beta / 30D Vol 0.82β · 45% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 57.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 51
RSI-14: 51.2 · SMA20: $447.57 · SMA50: $419.10

6-Pillar Scorecard Institutional Category Breakdown (SYK 2 – 4 ISRG)

Columns: Metric · SYK · ISRG
1. Valuation Multiples SYK
Forward P/E 19.0x 35.6x
Trailing P/E 33.3x 53.2x
PEG Ratio 1.54x 2.02x
EV / Revenue 5.0x 13.2x
2. Growth & Scale ISRG
Revenue Growth (YoY) +7.6% +21.7%
Earnings Growth (YoY) -11.7% -23.6%
TTM Revenue (USD) $26.3B $11.6B
Market Cap $118.9B $152.5B
3. Profitability & Quality ISRG
Gross Margin 65.7% 66.6%
Operating Margin 24.0% 31.7%
Net Profit Margin 13.8% 25.5%
Return on Equity (ROE) 16.0% 17.9%
4. Balance Sheet & Cash Flow ISRG
Cash Generation (TTM) $4.57B $3.60B
Cash Flow Margin 17.4% 31.1%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $46.12 Book/Sh · 17.9% ROE
Dividend Yield 1.10% None (0.00%)
5. Options & Positioning SYK
Options Structure Phase SURGE SURGE
Current IV / %ile 28.1% (5th %ile) 31.8% (16th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.66x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat ISRG
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 34.9% of Rev ($4.04B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (3) vs ISRG (7)
Institutional Metric SYK ISRG Criterion Row Edge
Market Capitalization
Scale
$118.9B $152.5B Larger Scale ISRG
Trailing P/E Ratio
Valuation
33.3x 53.2x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 35.6x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+7.6% +21.7% Higher Growth ISRG
Operating Margin (TTM)
Profitability
24.0% 31.7% Higher Margin ISRG
Net Profit Margin
Profitability
13.8% 25.5% Higher Margin ISRG
Return on Equity (ROE)
Capital Efficiency
16.0% 17.9% Higher ROE ISRG
52-Week Range Position
Momentum
36% ($267–$389) 40% ($329–$604) Stronger Trend ISRG
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.82β · 45% Vol Lower Realized Risk ISRG
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 43.4 / 100 (HOLD) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $11.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 66.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 2.02x PEG · 13.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $3.60B ($46.12 Book/Sh · 17.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYK +2.47 pp
SYK: +5.47% · ISRG: +3.0%
3M Horizon ISRG +18.56 pp
SYK: -6.21% · ISRG: +12.35%
6M Horizon ISRG +0.68 pp
SYK: -0.78% · ISRG: -0.1%
1Y Horizon SYK +5.51 pp
SYK: -16.77% · ISRG: -22.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue ISRG Revenue SYK Op. Margin ISRG Op. Margin Margin Leader
FY2018 $13.6B $3.72B 18.7% 32.2% ISRG
FY2019 $14.9B $4.48B 18.2% 30.7% ISRG
FY2020 $14.3B $4.36B 15.5% 24.1% ISRG
FY2021 $17.1B $5.71B 15.1% 31.9% ISRG
FY2022 $18.4B $6.22B 15.4% 25.3% ISRG
FY2023 $20.5B $7.12B 19.0% 24.8% ISRG
FY2024 $22.6B $8.35B 16.3% 28.1% ISRG
FY2025 $25.1B $10.1B 19.5% 29.3% ISRG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ISRG SURGE
8d in phase · OBV DISTRIBUTION
Current IV 31.8%
IV Percentile 16th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ISRG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
ISRG Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $152.5B market capitalization and 31.7% operating margin.
OpEx & R&D Reinvestment 34.9% of Rev ($4.04B)
90D Engineering Disclosures 0 Published · Robot Manipulation

Investor FAQ SYK vs ISRG Key Questions & Quantitative Answers

As of Nov 16, 2026, Intuitive Surgical Inc. (ISRG) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas ISRG carries 43.4/100 (HOLD) at $439.50 (35.6x Forward P/E, 31.7% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. ISRG 43.4/100 HOLD), ISRG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (31.7% vs. 24.0% operating margin) and revenue trajectory (+21.7% vs. +7.6% YoY).

ISRG leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with ISRG at +21.7% YoY revenue growth and -23.6% YoY earnings growth on $11.6B TTM revenue (66.6% gross margin, 31.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while ISRG shifted +170.4%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 34.9% of Rev ($4.04B) (0 disclosures) for ISRG.

SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas ISRG trades at 35.6x Forward P/E, 53.2x Trailing P/E, 2.02x PEG, and 13.2x EV/Revenue (31.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus ISRG (17.9% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, ISRG carries 31.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.82β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.